Toll-free:400-690-0195 English 中文版
   
miRNA Inhibitor
GenePharma miRNA inhibitors are chemically-modified and optimized nucleic acids designed to specifically target the microRNA (miRNA) molecules in cells. Endogenous microRNAs are small
 

General Transfection Starting Points for microRNA inhibitors in Cultured Mammalian Cells

 

 

 

Plate Format

96 wells

24 wells

12 wells

6 wells

Transfection Reagenta

0.3–1.0 μL

1–3 μL

2–4 μL

3–6 μL

miRNA Inhibitorsb

3 pmol

15 pmol

30 pmol

75 pmol

Cell Density c

6,000 cells/well

40,000 cells/well

80,000 cells/well

200,000 cells/well

Final Volume per Well

0.1 mL

0.5 mL

1.0 mL

2.5 mL

 

 

 

a Refer to the instructions provided with your transfection reagent for the recommended volume.

The amount shown results in a final miRNA inhibitors concentration of 30 nM. The amount of miRNA inhibitors required for maximal miRNA inhibitors activity will vary among cell types. For a 96-well plate and 100 μL final transfection volume, 3 pmol of a 5 μM oligonucleotide solution is 0.6 μL. Robotic pipettors may require volumes of 2–5 μL for accurate pipetting. To increase pipetting volumes and accuracy when preparing transfection complexes, we recommend first making a plate with a dilution of your stock oligonucleotide

Optimal cell density will vary among cell types, depending on cell size and growth characteristics. In general, we recommend 30–70% confluency.

 

 

 

Transfection Optimization
Optimizing transfection efficiency is crucial for maximizing miRNA inhibitors activity while minimizing cytotoxicity. Optimal transfection efficiencies are achieved by identifying an effective transfection reagent for each cell type and by adjusting (in order of importance):
● Amount of transfection reagent
● Amount and type of RNA oligonucleotide
● Cell density at the time of transfection
● Order of transfection (pre-plating cells or plating cells/transfecting in tandem)
● Length of exposure of cells to transfection reagent/microRNA inhibitors complexes

Most protocols recommend maintaining mammalian cells in the medium used for transfection; this avoids dilution or removal of RNA oligonucleotides from the cells by adding medium or washing the cells with new medium too soon after transfection. We have found that cells typically exhibit greater viability when existing medium is replaced with fresh medium 24 hours after transfection. Replacing medium after 24 hours generally does not change the activity of the transfected miRNA inhibitors. Once the conditions for optimal transfection efficiency are determined, they should be kept constant from experiment to experiment for a given cell type.

 

 

 

References:

 

 

1. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, Bartel DP, Linsley PS, Johnson JM. (2005) Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 433(7027):769–773.

2. Lee RC, Feinbaum RL, Ambros V (1993) The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75(5):843–854.

3. Wightman B, Ha I, Ruvkun G (1993) Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 75(5):855–862.

4. Yekta S, Shih IH, Bartel DP. 2004. MicroRNA-directed cleavage of HOXB8 mRNA. Science
304(5670):594–596.

5. Bagga S, Bracht J, Hunter S, Massirer K, Holtz J, Eachus R, Pasquinelli AE (2005) Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation. Cell 122(4):553–563.

6. Jing Q, Huang S, Guth S, Zarubin T, Motoyama A, Chen J, Di Padova F, Lin SC, Gram H, Han J (2005) Involvement of microRNA in AU-rich element-mediated mRNA instability. Cell 120(5):623–634.

7. Schramke V, Sheedy DM, Denli AM, Bonila C, Ekwall K, Hannon GJ, Allshire RC. 2005.
RNA-interference-directed chromatin modification coupled to RNA polymerase II transcription. Nature
435(7046):1275–1279.

8. Bustin SA (2002) Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): trends and problems. J Mol Endocrinol. 29(1):23–39.

QUALITY CONTROL

Purity:

Analytical HPLC of a sample of purified single-stranded RNA oligonucleotide is used to confirm ≥97% purity.

 
Description
Experimental
Usage
Application
Ordering